RHBC
NTLA icon

R.H. Bluestein & Co’s Intellia Therapeutics NTLA Stock Holding History

R.H. Bluestein & Co’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,000
Closed -$236K – 404
2021
Q4 		$236K Hold
2,000
– – 0.01% 366
2021
Q3 		$268K Hold
2,000
– – 0.01% 348
2021
Q2 		$324K Buy
+2,000
New +$156K 0.01% 312

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

R.H. Bluestein & Co's NTLA Position: Q1 2022 in Review

R.H. Bluestein & Co sold out of Intellia Therapeutics (NTLA) in Q1 2022, closing a stake of 2,000 shares — an estimated $236K sold.

R.H. Bluestein & Co first reported a position in NTLA in Q2 2021 and held it in 3 quarters. The position peaked at $324K in Q2 2021. 348 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

  • R.H. Bluestein & Co reported no remaining Intellia Therapeutics position as of Q1 2022 after selling out during the quarter.
  • R.H. Bluestein & Co sold 2,000 Intellia Therapeutics shares in Q1 2022, an estimated $236K.
  • R.H. Bluestein & Co first reported a position in Intellia Therapeutics in Q2 2021 and held it in 3 quarters.
  • R.H. Bluestein & Co's Intellia Therapeutics position peaked at $324K in Q2 2021.
  • 348 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on R.H. Bluestein & Co's 13F filing for Q1 2022, filed 11 May 2022.